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H
ealth care systems have played a
central role in the public health re-
sponse to the growing problem of
diabetes (1–2) and its complications.
During the 1990s, managed care organi-
zations (MCOs) began seeking system-
level approaches to improve diabetes
outcomes and control costs in covered
populations. Although previous clinical
trials(3–6)haddemonstratedthatseveral
clinical interventions could reduce com-
plication rates and possibly control costs,
these ﬁndings were not being systemati-
cally applied (7,8).
Performance-reporting initiatives,
such as the National Committee on Qual-
ityAssurance’sDiabetesQualityImprove-
ment Program (9), led MCOs to develop
disease management programs that used
diabetes registries, internal performance
monitoring and feedback, physician and
patient reminder systems, case manage-
ment, and provider incentives to improve
quality (10,11). Simultaneously, MCOs
introduced cost-containment strategies,
including utilization review, preauthori-
zation requirements, cost-related incen-
tives, and patient cost-sharing (12).
MCO structures ranged from de-
cades-old not-for-proﬁt group/staff
model HMOs to contractual arrange-
ments between traditional indemnity in-
surers and newly formed provider groups
or individual providers. Provider groups
ranged from relatively integrated multi-
specialty group practices to loosely afﬁli-
ated physician networks or independent
practice associations (IPAs). This hetero-
geneity persists today; however, neither
structural variation nor disease manage-
ment strategies have been carefully stud-
ied for their associations with diabetes
care quality or patient outcomes.
In1998,theCentersforDiseaseCon-
trol and Prevention and the National In-
stitute of Diabetes and Digestive and
Kidney Diseases launched a multicenter,
prospective observational study, the
Translating Research into Action for Dia-
betes (TRIAD) Study (13). The TRIAD
Study Group includes investigators from
six translational research centers that
partnered with ten health plans. These
plans contracted with 68 provider groups
to deliver primary and specialty care to
more than 180,000 diabetic enrollees in
1998. From this population, TRIAD as-
sembled one of the largest cohorts of dia-
betic patients ever studied, collecting and
linking data from patients, providers,
provider groups, and health plans.
TRIAD assessed associations between
system-level structures and strategies and
the quality of diabetes care and patient
outcomes using Donabedian’s paradigm
(14) (Fig. 1). TRIAD also studied patient-
level characteristics that may inﬂuence
outcomes, either directly by affecting pa-
tients’ abilities to self-manage diabetes or
indirectly by affecting interactions with
health care systems (Fig. 2). In Fig. 2, we
synthesize published TRIAD studies that
addressedtheinﬂuencesofeithersystem-
level or patient-level characteristics on
processes or outcomes for diabetic
patients.
RESEARCH DESIGN AND
METHODS— TheoriginalTRIADco-
hort consisted of a geographically, ra-
cially, and socioeconomically diverse
group of U.S. adult (aged 18 and above)
diabetic patients. They were selected, us-
ing a standardized algorithm, (13) from
diabetic patients who, in 1999, had been
enrolled in one of the ten participating
health plans for at least 18 months. The
cohort was surveyed three times by com-
puterized telephone or mailed survey in
2000–2001, 2002–2003, and 2005 (Fig.
3). The numbers of participants (and re-
sponse rates adjusted for inability to con-
tact and mortality) were 11,927 (69%),
8,781 (83%), and 5,751 (75%), respec-
tively. The majority of the participants’
medical records were obtained and re-
viewedattheﬁrsttwosurveys.Thecohort
was linked to the U.S. Census Bureau’s
Census2000blockgroupstoobtainmea-
sures of neighborhood socioeconomic
status (SES) and annually to the Centers
for Disease Control and Prevention’s Na-
tional Death Index to obtain mortality.
For the ﬁrst survey, each participating
health plan’s medical director and a repre-
sentativefrom63ofthe68providergroups
were interviewed. For the second, partici-
pants’ primary care physicians were sur-
veyed by mail for physician demographics,
knowledge, and attitudes toward MCO
structure and strategies (n  1,248 physi-
cian respondents, 54% response rate).
TRIAD survey instruments are available at
http://www.triadstudy.org.
In2005,TRIADﬁndingsledstudyre-
searchers to develop a Cardiovascular
Disease(CVD)RiskSurveyfocusedonpa-
tient-leveldeterminantsofriskfactorcon-
trol for blood pressure, A1C, and LDL
cholesterol in seven of the original ten
TRIADplans.Usingtelephoneormail,re-
searchers surveyed patients who were ei-
ther in “good control” of all three risk
factors (i.e., A1C 8%, LDL cholesterol
130 mg/dl, and systolic blood pressure
[SBP] 140 mmHg) or in “poor control”
ofatleasttworiskfactors(i.e.,valuesator
above these cut points). Data were col-
lected on patients’ perceptions of risks,
self-efﬁcacy, communication with their
providers, access to care, cost barriers,
self-reported adherence to a regimen of
prescribed medications, and reasons for
nonadherence.
In 2006, TRIAD investigators
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1–4 health plans that evaluated natural
experiments such as plan-speciﬁc disease
management interventions, changing
health insurance beneﬁts, and the effects
of Medicare Part D. Other theme studies
explored determinants of medication ad-
herence and health disparities.
All TRIAD ﬁndings reported herein
are based on the results from multivari-
able hierarchical models that account for
the nesting of patients within provider
groupsandprovidergroupswithinhealth
plans. System-level characteristics and
strategies were incorporated as second-
level ﬁxed effects in patient-level regres-
sions. Reported associations are statistically
signiﬁcant (P  0.05) unless otherwise
stated.
STUDY FINDINGS
Managed care structure
Four of TRIAD’s ten health plans self-
identiﬁed as for-proﬁt organizations and
six as not-for-proﬁt. Physician groups
self-identiﬁed as either group/network
models(n25),IPAs(n25),orgroup/
staffmodels(n18).Processmeasuresof
care quality were quite high across all
plans (15), but among for-proﬁt plans,
patients in group/network model ar-
rangements were at least 10% more likely
to receive six of seven recommended
“processes of care” than were patients in
IPA arrangements (16). The proﬁt status
of health plans was not signiﬁcantly asso-
ciated with process scores.
Disease management strategies
Fromthemedicaldirectors’survey,inten-
sity scores were produced that measured
the extent to which plans and provider
groups used six disease management
strategies: 1) performance feedback to
physicians,2)physicianreminders,3)use
Figure 1—TRIAD conceptual model for relationships of system-level factors, processes, and
outcomes of care. LDL-c, LDL cholesterol. ESRD, end-stage renal disease.
Figure2—TRIADconceptualmodelforrelationshipsofpatientfactorsandpatient-systeminteractionswithprocessesandoutcomesofcare.LDL-c,
LDL cholesterol.
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ers, 5) formal care/case management by
nonphysicianproviders,and6)healthed-
ucation resources (17). The latter four
were highly correlated and were com-
bined into a structured care management
score. Researchers assessed associations
of these intensity scores with care pro-
cesses, cardio-metabolic risk factor con-
trol, and risk factor management (17,18).
Greater intensity of performance
feedback, physician reminders, and
structured care management were each
strongly associated with better care pro-
cesses (17). For ﬁve to six of the eight
processes listed in Fig. 1, provider groups
at the 3rd versus the 1st tercile of each
intensity score had a 5–15 percentage
point better compliance with recom-
mendedprocessmeasures.Incontrast,no
intensity score was related to better A1C,
LDL cholesterol, or blood pressure con-
trol or to the intensity of pharmacother-
apy for these risk factors.
Process of care rankings of provider
groups were entirely unrelated to the
groups’rankingsforpatientA1Corblood
pressure control and only weakly associ-
atedwithrankingsbypatientLDLcholes-
terol levels (18). Thus, simple process of
care indicators should not be interpreted
as meaningful proxies for the quality of
clinical care or the health status of pa-
tients.
Quality of care at TRIAD plans was
compared with that of ﬁve geographically
matched Veterans’ Administration (VA)
health care centers in 2000 (15). The VA
centers performed signiﬁcantly better on
all seven process measures. Importantly,
VAcenterpatientsalsohadhighercontrol
rates for A1C and LDL cholesterol (A1C
8.5%: 83 vs. 65%; LDL cholesterol
100mg/dl:86vs.72%).Bloodpressure
control and patient satisfaction measures
did not differ signiﬁcantly.
Physician reimbursement and
incentives
Attheinitialsurvey,providergroupmed-
ical directors reported that physician re-
imbursementrangedfrom100%salaryto
100% fee-for-service. Performance-
related incentive pay linked to either
quality of care, utilization, or both also
varied widely. Patients of providers reim-
bursed predominantly through salary
were more satisﬁed, had signiﬁcantly
higher eye and foot examination rates,
signiﬁcantly more frequent tests for albu-
minuria, and better glycemic control
(19). Incentive pay related to quality was
associated with better performance on
several care processes and with greater
patient satisfaction. However, the rela-
tively small number of provider groups
made it difﬁcult to distinguish the impact
ofreimbursementandincentivestrategies
from other aspects of the medical groups.
Thus, when analyses were adjusted for
group type (medical group vs. IPA), these
differences diminished and most were no
longer signiﬁcant. Findings were similar
when reimbursement information was
obtained directly from the TRIAD physi-
cian survey (20).
Cost-containment strategies
Among TRIAD health plans, various pro-
cesses of care did not differ by the pres-
ence or intensity of utilization-based
physician incentives or referral manage-
ment strategies (e.g., prior authorization,
gate-keeping, physician proﬁling) (21).
Furthermore, participants in plans using
referral management did not report lower
specialist visit rates or greater difﬁculty
getting specialty referrals. Thus, physi-
cian incentives based on controlling costs
didnotappeartoadverselyaffectdiabetes
care (22,23).
In contrast, strategies that increased
patientcostswereassociatedwithadverse
consequences. Participants having full
coverage for selected services were more
likelythanthosewithoutcoveragetohave
had a retinal examination (78.4 vs.
69.8%) or to have attended a diabetes ed-
ucation session within the past year (28.8
vs. 18.8%) and, among insulin users, to
practice daily self-monitoring of blood
glucose (SMBG) (74.8 vs. 58.6%) (24).
Patients with partial coverage (e.g., co-
payments, coinsurance) had similar rates
of retinal examinations and health educa-
tion class attendance to those with full
coverage, but lower rates of SMBG (68.0
vs. 74.8%). Among the third-survey re-
spondents (2005), 14% reported using
less medicine than recommended be-
cause of costs. Compared with having
Figure 3—TRIAD timeline and component studies.
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$50, costs of $150 or more were associ-
ated with greater medication underuse
(24 vs. 7%) (25). At the second survey,
patients reporting that out-of-pocket
costs were a barrier to self-management
were signiﬁcantly less likely to be in good
control of all three cardiometabolic risk
factors (26).
Implementation of Medicare Part D’s
prescription drug coverage in 2006 intro-
duced a new coverage gap for many older
TRIADpatients.Commonlyreferredtoas
the “doughnut hole,” this gap began after
the ﬁrst $2,250 of prescription costs. In
two TRIAD plans, 25% of diabetic
Medicare enrollees entered the gap dur-
ing 2006 (27). This proportion was lower
than had been projected, possibly be-
cause both plans effectively encouraged
greater use of generic medications. Nev-
ertheless, compared with patients with-
out coverage gaps, patients with only Part
D reported cost-related medication non-
adherenceandhadlowerobservedadher-
ence for antidiabetic, antihypertensive,
and lipid-lowering medications (28,29).
Other system interventions
TRIAD theme studies evaluated several
health system interventions (30–34).
One group-model plan used electronic
health record dates to link prescription
ﬁlls with recent measures of A1C, LDL
cholesterol, and SBP. Of patients not in
control for each risk factor, only 20–23%
had evidence of poor medication adher-
ence; from 30 to 47% were adherent to
prescribed medications but had not re-
ceived treatment intensiﬁcation in re-
sponse to elevated risk factor levels (30).
These ﬁndings emphasize the potential
utility of electronic clinical data for mon-
itoring and improving evidence-based
processesofcare,suchastreatmentinten-
siﬁcation (35,36), which has been shown
to improve patient outcomes (37).
One TRIAD plan evaluated a nurse
care management program that sought to
enroll all diabetic patients with poor A1C
control,microalbuminuria,orrecenthos-
pitaloremergencydepartmentvisits(32).
Despite a large staff deployment, only
22% of the eligible patients were enrolled
during 2004, in part because many non-
targeted patients were enrolled and also
because many patients were retained
longer than the planned 6 months (me-
dian 8 months). Compared with matched
eligible but unenrolled patients, enrollees
had 0.3–0.5% greater improvement in
A1C levels 12 months later, and slightly
betterLDLcholesterolandbloodpressure
levels.Duringfollow-up,bothgroupsim-
proved substantially on all three mea-
sures, suggesting that usual primary care
may have sufﬁced for many.
Another plan changed from requiring
appointments to providing open-access
visits (32). After adjustment for differ-
encesinbaselinerates,thesixclinicswith
open access had lower rates of A1C and
microalbuminuira testing and poorer
blood pressure control than six clinics
that required appointments.
The TRIAD CVD Risk Survey (38)
found that missing medications was asso-
ciated with poor risk factor control. Rea-
sons for missing medications included
transportation difﬁculties to pharmacies
and pharmacies not having prescribed
medications. In a follow-up study in one
TRIAD plan, adherence to antidiabetic,
antihypertensive, and lipid-lowering
medications was higher among diabetic
patients who reﬁlled prescriptions by
mail rather than in person (33).
Although TRIAD did not ﬁnd associ-
ations of disease management strategies
with better risk factor control in 2000,
TRIAD health plans did observe marked
improvements in control from 2001 to
2006. In one plan (34), an extensive
chronic care model–based diabetes disease
management program was implemented.
Clinically important improvements in A1C
and LDL cholesterol control, smaller but
signiﬁcant improvements in SBP, and im-
provementsinallservicesclassiﬁedasapro-
cess of care were observed.
PATIENT FACTORS— The lack of
association of system-level factors with
patient outcomes led TRIAD researchers
toward a conceptual model (Fig. 2) that
emphasizes patient-level factors as deter-
minants of outcomes.
Sociodemographic characteristics
Notable differences in intermediate and
longer term outcomes and smaller differ-
ences in processes of care were observed
across patient subgroups. Younger dia-
betic patients were consistently less likely
to receive recommended care processes;
more likely to have missed a recom-
mended process for an entire 3-year pe-
riod (a “persistent lapse”) (39); and less
likely to have good concurrent control of
A1C, LDL cholesterol, and SBP at the sec-
ond examination (26) and 6 years later in
one TRIAD plan (40). Moreover, their
treatment was less likely to be intensiﬁed
for poorly controlled blood pressure and
LDL cholesterol, and only slightly more
likely for poorly controlled A1C.
Sex differences were relatively small
(41–43), but for patients with known
CVD,womenwerelesslikelythanmento
beusingaspirin(33.2vs.39.0%)orlipid-
lowering agents (52 vs. 58%) (41) and
less likely to be in control for blood pres-
sureandLDLcholesterol(44).Inpatients
without CVD, women were less likely to
have had a recent lipid proﬁle (54 vs.
58%) or to have been advised to use aspi-
rin (27 vs. 33%). In the 2005 single plan
study(43),womenremainedsigniﬁcantly
less likely than men to be in control for
both LDL cholesterol (47 vs. 55%) and
blood pressure (52 vs. 60%).
Race/ethnicity was not consistently
related to differences in care processes
(44,45), but important, consistent differ-
ences in control of all three intermediate
outcomes were observed (26,38,44). Af-
rican Americans had the poorest blood
pressurecontrol:45%hadbloodpressure
140/90 mmHg versus 56% of whites.
Mean LDL cholesterol levels were signiﬁ-
cantly greater for African American pa-
tients than white patients (118 vs. 111
mg/dl). All three minority populations
had slightly but signiﬁcantly higher A1C
levels than whites (44). African Ameri-
cansweremorefrequentlyinpoorcontrol
of at least two risk factors at the second
survey (2002) (26) and again in the 2005
CVD Risk Survey (38). Their poorer con-
troloccurreddespitecomparableormore
intensive treatment (see below).
Neither household income nor edu-
cation was strongly associated with pro-
cesses of care, but they were associated
withintermediateoutcomesandalsowith
mortality.Ofprocessmeasures,onlyrates
of dilated eye exams differed, being lower
among poor or less educated respondents
(75%ineachgroup)comparedwithmore
educated patients or those making over
$75,000 annually (80 and 85%, respec-
tively) (44). Persistent lapses in care pro-
cesses were only slightly less frequent in
people with higher household incomes
and did not differ by education (39).
Higher incomes and greater education
were independently related to being in
control for all three risk factors simulta-
neously. Poor control was more common
in participants who expressed concerns
about cost as a barrier to medical care
(26).
TRIAD examined the independent ef-
fects of neighborhood SES to determine
whether the social and spatial separation
of poorer neighborhoods with fewer re-
The TRIAD Study Group
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to disparities. After adjustments for indi-
vidual income, education, and objective
measures of neighborhood SES, partici-
pants reporting greater neighborhood
problems were more likely to smoke, less
likelytoparticipateinregularphysicalac-
tivity,andhadworseself-reportedmental
andphysicalhealthscores(46).Objective
andsubjectivemeasuresofneighborhood
problems were independently associated
with poorer blood pressure control.
Health behaviors
Many associations of health-related be-
haviors with outcomes were found, but
they were modest in strength and ex-
plained little of the sociodemographic
differences in outcomes. Fully 50% of
patients 25–44 years of age with less than
a high school education were current
smokers compared with 7% of college-
educated people age 65 and above
(47,48). Smoking prevalence did not dif-
fer by race/ethnicity, but was higher
among Spanish-speaking Latino patients.
Current smoking was a strong and inde-
pendentpredictorofpoorriskfactorcon-
trol (26), but adjustment for smoking did
not reduce associations of younger age
or lower educational level (SES) with
control.
Daily walking for at least 20 min was
less frequent in patients older than 65
years of age than in younger patients (64
vs. 70%); in women less frequent than in
men (65 vs. 70%); and in whites or Afri-
can Americans less frequent than in
Asian/Paciﬁc Islanders or Latino patients
(49). Less education was also associated
withalowerlikelihoodofregularphysical
activity(48).Aswithsmoking,regularac-
tivitywasanindependentpredictorofbe-
ing in good control but did not explain
age or SES differences in control (26).
Among insulin users, Latinos re-
ported lower rates than whites of SMBG
(62 vs. 77%) (48). SMBG did not vary by
SES. African Americans and Latinos re-
ported spending about 5% more time
than whites on several diabetes self-care
behaviors including foot care, shopping
for and cooking diabetic meals, and exer-
cisingtomanagediabetes(50).Patientsof
lower SES reported spending more time
than higher SES patients on self-care, but
less time using health-related websites or
participating in support groups (50).
Lower income patients were more
likelytounderuseprescribedmedications
duetocosts(15vs.5%)(25).Afteradjust-
mentforincome,Latinos’cost-relatedun-
deruse of medications was slightly greater
than that of other groups (14 vs. 7–11%)
(25).
Clinical and psychosocial factors
Depression, measured by the Patient
Health Questionnaire 8 (PHQ-8) (51),
was more prevalent, more often un-
treated, and more strongly associated
with poor risk factor control in African
American patients (adjusted odds ratio
[OR] 2.28 [95% CI: 1.09–4.74]) than in
whites (adjusted OR 1.04 [0.63–1.72])
(38).
Morethan50%ofTRIADparticipants
were obese (BMI 30 kg/m
2) at baseline.
Obesity was more frequent in women
than men (61 vs. 51%) and in African
American participants and was associated
with lower likelihood of regular walking
(49). Obesity was also associated with a
lowerlikelihoodofbeingincontrolforall
threecardio-metabolicriskfactorsbutex-
plainedlittleofthepoorerriskfactorcon-
trol in African Americans (26).
Physicians managed medications dif-
ferently by patient race/ethnicity. African
Americans, Latinos, and Asians/Paciﬁc Is-
landers received similar or more intense
pharmacotherapy than whites for hyper-
tension and lipid management (44) and
weremorelikelytoreceiveintensiﬁcation
for poor blood pressure control than
whites (52). By contrast, all nonwhite
groups were less likely than whites to be
intensiﬁed for poorly controlled A1C
(52).
PATIENT-SYSTEM
INTERACTIONS
Communication
Patientassessmentsofproviders’abilityto
listen, explain, respect, and spend time
with the patient were unrelated to risk
factor control (26), did not explain edu-
cational disparities in health behaviors
(smoking, physical activity, diabetes-
related health seeking activity) (48), and
didnotlessenthenegativeimpactofcost-
sharingonuseofSMBG,healtheducation
classes, or annual retinal examinations
(24). However, patients reporting greater
trust in their physicians were more likely
tobeingoodcontrolofallthreeCVDrisk
factors(26).However,differencesintrust
did not explain racial/ethnic control dif-
ferences. In one TRIAD plan, reported re-
ceipt of advice on physical activity or
dietary changes was not associated with
differences in these behaviors among
women with gestational diabetes mellitus
(53).
Most Spanish-speaking TRIAD pa-
tients lived in south Texas. Nearly 90%
reported having a bilingual physician. In
this context, SMBG rates were similar and
dilated eye exam rates (84 vs. 81%) and
foot self-care rates (76 vs. 70%) were
higher for Spanish-speaking versus En-
glish-speaking Latino patients (48). Never-
theless, mean A1C levels were somewhat
higher for Spanish-speaking versus En-
glish-speaking Latinos (9.1 vs. 8.8%).
Intensity of disease management (in
2000) did not appear to affect racial/
ethnicdisparitiesinriskfactorcontrol,ﬂu
vaccination rates, or intensity of medica-
tion management for elevated risk factors
either positively or negatively (54). Simi-
larly, educational disparities in smoking,
physical activity, and various health-
seeking behaviors were unrelated to the
intensity of disease management (47).
STUDY LIMITATIONS— Most
TRIAD analyses were cross-sectional,
which leaves open a possibility that sys-
tem-level interventions such as disease
management may have affected patient
outcomes if observed for a longer period.
However, our study focused on interme-
diate outcomes that change more rapidly
and on well-established programs de-
scribed in medical director interviews.
System-level interventions have evolved
markedly since 2000; the lack of associa-
tion of programs with outcomes in 2000
maynotgeneralizetothecurrentcontext.
As noted, the relatively small number of
healthplansand,toalesserextent,ofpro-
vidergroupsintheTRIADsamplemadeit
difﬁcult to study more than one system-
level characteristic at a time. TRIAD pa-
tients were drawn from a diverse set of
plan types, which should enhance gener-
alizability. However, all plans partici-
pated voluntarily and all scored relatively
high in performance (15). A broader
range of plans may have enhanced our
abilitytodetectassociationsofsystemfac-
tors with quality and possibly with risk
factor levels. Whether our ﬁndings for
physician incentives, performance feed-
back, and physician reminders generalize
to non–managed care settings cannot be
examinedinTRIAD,butweseenoreason
why patient-level associations we ob-
served should differ.
SYNTHESIS AND
IMPLICATIONS— TRIAD found
that more integrated health systems—
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ease management strategies and using
ﬁnancial incentives related to quality—
achieved higher levels of diabetes care
processes. However, these strategies were
not associated with better intermediate
outcomes. A similar “disconnect” be-
tweenimprovedprocessesandunaffected
outcomes has been reported elsewhere
(55,56). Process measures are more di-
rectly under the control of providers than
outcomes. A logical conclusion is that
systems should speciﬁcally focus on im-
proving processes of care, but only on
processesshowntobelinkedtoimproved
outcomes (e.g., use of statins, ACE inhib-
itors, aspirin, and treatment intensiﬁca-
tion for poor risk factor control) (35–37).
The proposition that well-planned
system-level interventions can ultimately
improve patient outcomes found some
support in TRIAD in the superior inter-
mediate outcomes of the VA, a highly in-
tegrated system with excellent clinical
dataandstrongqualityimprovementpro-
grams, and in the recent outcome im-
provements reported by at least one
TRIAD plan (34).
Strategies of shifting health care costs
to patients through co-payments or cov-
erage gaps reduced the use of both pre-
ventive services and recommended
medications—especially for lower-
income patients. Cost-shifting among pa-
tients with chronic illnesses does not save
money and is associated with higher rates
of hospitalization and death (57). It is
ironic that a health plan’s cost-shifting
strategies may undermine the large in-
vestments it makes in disease manage-
ment. One TRIAD plan is currently
evaluating a beneﬁts program for diabetic
patients that eliminates all copayments
for evidence-based diabetes medications
(58).
TRIAD has found numerous associa-
tions of patient-level sociodemographic,
psychosocial, and behavioral factors with
both self-care and intermediate outcomes
that suggest that the next generation of
system-levelinterventionscouldbebetter
tailoredtomeettheneedsofdiabeticsub-
populations. Younger patients, who are
the most likely to beneﬁt from better risk
factorcontrol,(59)weretheleastlikelyto
be beneﬁting from system-level pro-
grams, having poorer care processes, risk
factor control, and self-care behaviors.
Fewer physician encounters, busier work
or family schedules, or less motivation
while still asymptomatic in this rapidly
growing segment of the diabetes popula-
tion may explain these disparities.
Modest disparities in risk factor man-
agement and control were noted between
males and females, whereas African
Americans and patients of lower SES
had much poorer control for CVD risk
factors. They also had higher rates of
obesity, cigarette smoking, undiagnosed
and untreated depression, greater sensi-
tivitytoout-of-pocketcosts,lowertrustin
physicians, and adverse neighborhood
environments. If future system-level in-
terventions can address these differences,
they will have a greater chance of reduc-
ing disparities and a greater net effect on
quality improvement. In fact, “one size
ﬁts all” interventions may exacerbate dis-
parities within populations, thereby lim-
iting the potential for quality and
outcome improvement (60).
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